Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adaptimmune
With
ICON plc
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 and \<75 years
Diagnosis of Esophageal cancer or Esophagogastric junction cancer.
Previously received treatment for advanced or metastatic disease.
Measurable disease according to RECIST v1.1.
HLA-A\*02 positive
Tumor shows MAGE-A4 expression confirmed by central laboratory.
ECOG Performance Status of 0 or1.
Left ventricular ejection fraction (LVEF) ≥50%.
You may not be if
1. Positive for any HLA-A\*02 allele other than: one of the inclusion alleles
2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study
3. Active autoimmune or immune mediated disease
4. Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases
5. Other prior malignancy that is not considered by the Investigator to be in complete remission. Clinically significant cardiovascular disease
6. Uncontrolled intercurrent illness
7. Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus
8. Pregnant or breastfeeding
Clareo Health | ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
